Steven Park to Humans
This is a "connection" page, showing publications Steven Park has written about Humans.
Connection Strength
0.344
-
Moore DC, Soni AC, Hu B, Smith ET, Levine J, Moyo TK, Jacobs R, Ghosh N, Park SI. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2022 Feb; 196(4):e30-e33.
Score: 0.043
-
Park S, Gale SE, Watson K. The Role of Testosterone in Patients With Heart Failure: A Systematic Review. Cardiol Rev. 2021 May-Jun 01; 29(3):156-161.
Score: 0.041
-
DiSogra KY, Tran T, Arnall JR, Janes A, Moore DC, Park SI. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. J Oncol Pharm Pract. 2021 Jul; 27(5):1265-1269.
Score: 0.040
-
Au KM, Wang AZ, Park SI. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma. Sci Adv. 2020 Apr; 6(14):eaaz9798.
Score: 0.038
-
Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. Ann Pharmacother. 2020 Apr; 54(4):371-379.
Score: 0.037
-
Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Target Oncol. 2019 Oct; 14(5):563-575.
Score: 0.037
-
Hill H, Arnall J, Janes A, Hatley C, Swift K, Hargett C, Howell T, Griffin S, Larck C, Park S. A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2019 Dec; 25(8):2041-2044.
Score: 0.035
-
Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 Jun 13; 7(11):2287-2296.
Score: 0.012
-
Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021 Dec 14; 5(23):5179-5189.
Score: 0.011
-
Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021 Nov 01; 96(11):1374-1384.
Score: 0.011
-
Hu B, Boselli D, Pye LM, Chen T, Bose R, Symanowski JT, Blackley K, Moyo TK, Jacobs R, Park SI, Soni A, Avalos BR, Copelan EA, Raghavan D, Ghosh N. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma. Cancer. 2021 Nov 01; 127(21):3991-3997.
Score: 0.011
-
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020 Sep 10; 38(26):3003-3011.
Score: 0.010
-
Au KM, Park SI, Wang AZ. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv. 2020 Jul; 6(27):eaba8564.
Score: 0.010
-
Ghosh N, Sanikommu S, Robinson M, Trivedi J, Brown T, Bose R, Park SI, Avalos BR, Copelan EA, Jacobs R, Hu B. Curative potential of chemoimmunotherapy in diffuse large B cell lymphoma with hepatic and/or renal dysfunction. Br J Haematol. 2019 Aug; 186(4):e65-e67.
Score: 0.009